Nearly 10% of Canadians report using cannabis for medical purposes, yet only 18% do so with a medical authorization and the support of a healthcare provider. This gap underscores a persistent disconnect between patient behaviour and clinical oversight, which is shaped in part by stigma, access barriers, and uncertainty around proper use. As a result, clinicians are increasingly looking for practical, evidence-informed guidance on how cannabinoid-based therapies can be integrated into care with clarity, safety, and confidence.
This June 11-12, Avicanna Inc. will host its 6th Annual Medical Symposium on cannabinoid-based medicine at the…
